Literature DB >> 7479744

Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression.

S J Orlow1, V J Hearing, C Sakai, K Urabe, B K Zhou, W K Silvers, B Mintz.   

Abstract

Cutaneous melanomas of Tyr-SV40E transgenic mice (mice whose transgene consists of the tyrosinase promoter fused to the coding regions of simian virus 40 early genes) strikingly resemble human melanomas in their development and progression. Unlike human melanomas, the mouse tumors all arise in genetically identical individuals, thereby better enabling expression of specific genes to be characterized in relation to advancing malignancy. The products of pigment genes are of particular interest because peptides derived from these proteins have been reported to function as autoantigens with immunotherapeutic potential in some melanoma patients. However, the diminished pigmentation characteristic of many advanced melanomas raises the possibility that some of the relevant products may no longer be expressed in the most malignant cells. We have therefore investigated the contributions of several pigment genes in melanotic vs. relatively amelanotic components of primary and metastatic mouse melanomas. The analyses reveal marked differences within and among tumors in levels of mRNAs and proteins encoded by the wild-type alleles at the albino, brown, slaty, and silver loci. Tyrosinase (the protein encoded by the albino locus) was most often either absent or undetectable as melanization declined. The protein encoded by the slaty locus (tyrosinase-related protein 2) was the only one of those tested that was clearly present in all the tumor samples. These results suggest that sole reliance on targeting tyrosinase-based antigens might selectively favor survival of more malignant cells, whereas targeting the ensemble of the antigens tested might contribute toward a more inclusive and effective antimelanoma strategy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479744      PMCID: PMC40754          DOI: 10.1073/pnas.92.22.10152

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation.

Authors:  R N Germain
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

Review 2.  Recognition of autoantigens by patients with melanoma.

Authors:  A N Houghton; S Vijayasaradhi; B Bouchard; C Naftzger; I Hara; P B Chapman
Journal:  Ann N Y Acad Sci       Date:  1993-08-12       Impact factor: 5.691

3.  Malignant melanoma in transgenic mice.

Authors:  M Bradl; A Klein-Szanto; S Porter; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

4.  Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes.

Authors:  T Wölfel; A Van Pel; V Brichard; J Schneider; B Seliger; K H Meyer zum Büschenfelde; T Boon
Journal:  Eur J Immunol       Date:  1994-03       Impact factor: 5.532

5.  Tyrosinases from two different loci are expressed by normal and by transformed melanocytes.

Authors:  M Jiménez; K Tsukamoto; V J Hearing
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

6.  Histopathogenesis of malignant skin melanoma induced in genetically susceptible transgenic mice.

Authors:  B Mintz; W K Silvers; A J Klein-Szanto
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

7.  Transgenic mouse model of malignant skin melanoma.

Authors:  B Mintz; W K Silvers
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

8.  Melanin biosynthesis patterns following hormonal stimulation.

Authors:  P Aroca; K Urabe; T Kobayashi; K Tsukamoto; V J Hearing
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

9.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Authors:  A B Bakker; M W Schreurs; A J de Boer; Y Kawakami; S A Rosenberg; G J Adema; C G Figdor
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

10.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  V Brichard; A Van Pel; T Wölfel; C Wölfel; E De Plaen; B Lethé; P Coulie; T Boon
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more
  6 in total

1.  Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models.

Authors:  N Le Fur; W K Silvers; S R Kelsall; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy.

Authors:  N Le Fur; S R Kelsall; W K Silvers; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

3.  A new transgenic mouse line for tetracycline inducible transgene expression in mature melanocytes and the melanocyte stem cells using the Dopachrome tautomerase promoter.

Authors:  Susan L Woods; J Michael Bishop
Journal:  Transgenic Res       Date:  2010-06-25       Impact factor: 2.788

4.  Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes.

Authors:  R F Wang; E Appella; Y Kawakami; X Kang; S A Rosenberg
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

Review 5.  Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146.

Authors:  Maria Cristina Rapanotti; Elena Campione; Giulia Spallone; Augusto Orlandi; Sergio Bernardini; Luca Bianchi
Journal:  Cell Death Discov       Date:  2017-03-06

6.  Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes.

Authors:  C Bertolotto; P Abbe; T J Hemesath; K Bille; D E Fisher; J P Ortonne; R Ballotti
Journal:  J Cell Biol       Date:  1998-08-10       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.